Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Marco Rizzo

Surgery of the Hand Rochester, MN Medical Doctor

NPI 1255310421 CMS profile 238380

200 1St St Sw, Rochester, MN 55905

Open in the dashboard

General payments

$48,430

79 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Marco Rizzo of Rochester, MN is reported in the CMS Open Payments database as having received $48,430 across 79 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Surgery of the Hand profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $7,648 10
2024 General $11,565 18
2023 General $5,092 6
2022 General $9,199 14
2021 General $1,784 6
2020 General $5,089 15
2019 General $8,053 10

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Marco Rizzo
  • Surgery of the Hand median
  • Middle half of Surgery of the Hand
  • National median

In program year 2025, general payments to Marco Rizzo were reported at $7,648. Among 286 Surgery of the Hand profiles paid that year, the median was $288 and the middle half received between $115 and $1,242.

Show as a table
Year Marco Rizzo Surgery of the Hand median Middle half National median
2019 $8,053 $369 $108–$1,516 $163
2020 $5,089 $153 $56–$898 $114
2021 $1,784 $261 $84–$1,296 $132
2022 $9,199 $313 $103–$1,562 $149
2023 $5,092 $241 $95–$876 $160
2024 $11,565 $236 $84–$890 $164
2025 $7,648 $288 $115–$1,242 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Synthes GmbH $47,403 66 payments
  2. DePuy Synthes Sales Inc. $305 4 payments
  3. Stryker Corporation $267 3 payments
  4. AxoGen $210 2 payments
  5. Smith+Nephew, Inc. $179 2 payments
  6. Integra LifeSciences Corporation $55 1 payment
  7. Endo Pharmaceuticals Inc. $12 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for serving as faculty or as a speaker for a medical education program $19,250 14 payments
  2. Travel and Lodging $14,766 23 payments
  3. Compensation for serving as faculty or as a speaker for an accredited or certified continuing education program $10,000 18 payments
  4. Food and Beverage $2,414 23 payments
  5. Consulting Fee $2,000 1 payment
Products named General payments · program years 2019–2025
  1. Avance Nerve Graft $210 2 payments
  2. VARIAX $162 1 payment
  3. T2 $106 2 payments
  4. Integra $104 1 payment
  5. VA-LCP PLATES & SCREWS $89 1 payment
  6. HEADLESS COMPRESSION SCREWS $89 1 payment
  7. NA $85 1 payment
  8. LCP $85 1 payment
  9. DYNOMITE $74 1 payment
  10. MCP $74 1 payment
  11. Other $346 6 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 4 drugs

Part D claims

67

Median for Hand Surgery: 118

Drug cost

$577

Median for Hand Surgery: $615

Branded share of claims

0%

Median for Hand Surgery: 34.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Celecoxib Generic 21 $246
Methylprednisolone Generic 17 $117
Oxycodone Hcl Generic 14 $109
Gabapentin Generic 15 $104

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,399 Part D prescribers listed as Hand Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 102 billing codes

Paid by Medicare

$181,992

Of which drugs: $24,695

Medicare patients

490

Average age 73

Services billed

2,122

282 women, 208 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 70%
High blood pressure 64%
Chronic kidney disease 26%
Diabetes 24%
Ischemic heart disease 20%
Depression 20%
Osteoporosis 20%
Cancer 18%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 152 339 $253

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

79 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Surgery of the Hand in Minnesota

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record